Vivitrol vs. Suboxone vs. Sublocade: Comparing MAT Medications

Key Takeaways

• Vivitrol (naltrexone), Suboxone (buprenorphine/naloxone), and Sublocade (extended-release buprenorphine) are all FDA-approved medications for opioid use disorder, but they work through different mechanisms
• Vivitrol is an opioid antagonist that blocks receptors entirely; Suboxone and Sublocade are partial agonists that activate receptors at a low level to reduce cravings and withdrawal
• Vivitrol requires full opioid detox before starting (7-14 days); Suboxone can be initiated during early withdrawal, and Sublocade requires stable Suboxone dosing first
• Clinical research, including the X:BOT trial, suggests comparable effectiveness when patients are able to initiate treatment successfully
• Cost, insurance coverage, and individual patient factors — not a blanket “better” medication — should guide the decision

Medication-Assisted Treatment (MAT): An evidence-based treatment approach combining FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. SAMHSA considers MAT the standard of care for opioid use disorder, with research consistently showing improved outcomes compared to behavioral treatment alone.

Three of the most widely prescribed MAT medications for opioid use disorder are Vivitrol, Suboxone, and Sublocade. Each approaches addiction treatment from a different pharmacological angle, and each has distinct advantages, limitations, and practical considerations. This comparison is intended to provide a factual framework for understanding the differences — the right choice for any individual depends on their clinical situation, treatment history, and personal circumstances.

Overview of the Three MAT Medications

Vivitrol (Extended-Release Naltrexone)

Vivitrol: A monthly intramuscular injection containing 380 mg of extended-release naltrexone. It is an opioid antagonist that blocks opioid receptors for approximately 30 days, preventing the euphoric effects of opioids and reducing cravings.

Vivitrol was FDA-approved for opioid use disorder in 2010. Its active ingredient, naltrexone, completely blocks opioid receptors without activating them. Manufactured by Alkermes, Vivitrol is administered once monthly by a healthcare provider.

Suboxone (Buprenorphine/Naloxone)

Suboxone: A sublingual film or tablet containing buprenorphine (a partial opioid agonist) and naloxone (an opioid antagonist added to deter injection misuse). It is taken daily, typically as a dissolving film placed under the tongue.

Suboxone received FDA approval in 2002 and has become the most widely prescribed MAT medication in the United States. The buprenorphine component partially activates opioid receptors — enough to reduce cravings and prevent withdrawal, but not enough to produce the full euphoric effects of heroin or fentanyl. Generic buprenorphine/naloxone formulations are available, making it the most affordable option in many cases.

Sublocade (Extended-Release Buprenorphine)

Sublocade: A monthly subcutaneous injection containing extended-release buprenorphine, manufactured by Indivior. It provides steady-state buprenorphine levels for approximately 30 days, eliminating the need for daily sublingual dosing.

Sublocade was FDA-approved in 2017 as a monthly injection for patients already stabilized on sublingual buprenorphine. It uses a delivery system that forms a solid deposit under the skin, gradually releasing buprenorphine over the course of a month. Patients must first be on a stable dose of transmucosal buprenorphine (such as Suboxone) for at least seven days before transitioning to Sublocade.

How They Work Differently

Opioid Agonist vs. Antagonist Approaches

The fundamental pharmacological distinction between these medications is the difference between agonist-based and antagonist-based treatment:

Feature	Vivitrol	Suboxone	Sublocade
Active ingredient	Naltrexone	Buprenorphine/naloxone	Buprenorphine
Mechanism	Full antagonist (blocks receptors)	Partial agonist (low-level activation)	Partial agonist (low-level activation)
Administration	Monthly IM injection	Daily sublingual film/tablet	Monthly subcutaneous injection
Detox required first	Yes (7-14 days opioid-free)	No (can start in early withdrawal)	Stable on Suboxone first
Controls withdrawal	No	Yes	Yes
FDA-approved for AUD	Yes	No	No

Partial Agonist: A substance that binds to and activates a receptor but produces a lower maximum response than a full agonist, even at full receptor occupancy. Buprenorphine’s partial agonism means it reduces cravings and withdrawal without producing the intense high associated with full opioid agonists.

Starting Requirements and Timing

One of the most clinically significant differences is the initiation process:

Vivitrol requires complete opioid detoxification. The patient must be opioid-free for 7 to 14 days, confirmed by clinical assessment and urine drug testing. This detox period is often the most challenging barrier, as many patients relapse during the gap between stopping opioids and starting Vivitrol.

Suboxone can be initiated while the patient is in early opioid withdrawal — typically 12 to 24 hours after the last opioid use for short-acting opioids, or longer for fentanyl. This ability to start treatment quickly, during the window when patients are most motivated, is considered a significant clinical advantage by many addiction medicine providers.

Sublocade requires the patient to already be stable on sublingual buprenorphine (Suboxone or equivalent) at a dose of 8 mg or higher for at least seven days. It is a continuation strategy, not a first-line initiation option.

Effectiveness and Research Comparisons

Clinical Trial Data

The most direct head-to-head comparison of these approaches is the X:BOT (Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment) trial, published in The Lancet in 2018. This NIDA-funded, multi-site randomized trial compared extended-release naltrexone (Vivitrol) with sublingual buprenorphine-naloxone (Suboxone) in patients with opioid use disorder.

Key findings from the X:BOT trial:

• Induction barrier: Significantly more patients randomized to Vivitrol failed to initiate treatment (28%) compared to Suboxone (6%), primarily because they could not complete the required detox period
• Among those who started: Once patients successfully initiated treatment, relapse rates were comparable between the two medications
• Overall intent-to-treat: When including all randomized patients (including those who failed to start), Suboxone showed better overall outcomes because more patients were able to begin treatment

These results highlight a nuanced reality: both medications are effective, but the detox barrier for Vivitrol means fewer patients access its benefits.

Real-World Outcomes

Real-world data from observational studies and treatment program outcomes generally align with the X:BOT findings. Both agonist-based (Suboxone/Sublocade) and antagonist-based (Vivitrol) approaches are associated with reduced opioid use, lower overdose rates, and improved treatment retention compared to no medication.

Retention rates vary by setting, but published data suggest that monthly injectable formulations (both Vivitrol and Sublocade) may have an advantage in retention over daily oral medications because they remove the daily adherence burden.

Cost, Insurance, and Accessibility

Price Comparisons

Without insurance, the cost differences are substantial:

• Suboxone (generic buprenorphine/naloxone) — approximately $100 to $300 per month for generic sublingual film
• Vivitrol — approximately $1,000 to $1,800 per monthly injection
• Sublocade — approximately $1,500 to $1,900 per monthly injection

Generic availability gives buprenorphine/naloxone a significant cost advantage. Neither Vivitrol nor Sublocade has a generic equivalent as of early 2026.

Insurance Coverage in NJ

In New Jersey, insurance coverage for MAT medications is generally robust:

• NJ Medicaid (NJ FamilyCare) — covers all three medications, though prior authorization requirements vary
• Private insurance — the Mental Health Parity and Addiction Equity Act requires coverage of SUD treatment; most plans cover these medications, though formulary placement and cost-sharing differ
• Medicare — covers Vivitrol and Sublocade under Part B (provider-administered injections) and Suboxone under Part D (prescription drugs)

Both Alkermes (Vivitrol) and Indivior (Sublocade) offer manufacturer patient assistance and co-pay programs for eligible patients.

Choosing the Right Medication

Factors That Influence the Decision

No single MAT medication is universally superior. The choice depends on individual clinical and practical factors:

• Ability to complete detox — patients who cannot safely detox or who have repeatedly relapsed during detox may be better candidates for buprenorphine-based treatment (Suboxone or Sublocade)
• Adherence concerns — patients with a history of medication non-compliance may benefit from monthly injectables (Vivitrol or Sublocade)
• Co-occurring alcohol use disorder — Vivitrol is the only one of the three with FDA approval for both opioid and alcohol use disorders
• Patient preference — some patients prefer antagonist-based treatment because they do not want to take any form of opioid; others prefer the comfort and withdrawal prevention of partial agonist treatment
• Treatment history — prior experience with these medications informs the decision. A patient who did well on Suboxone but struggled with daily adherence may be an ideal Sublocade candidate

Talking to Your Provider

The decision between these medications should be made collaboratively between the patient and their addiction medicine provider. The American Society of Addiction Medicine (ASAM) recommends that all three FDA-approved medications be available and that the choice be individualized based on the patient’s clinical profile, preferences, and circumstances.

Patients should feel empowered to ask:

• What are the advantages and disadvantages of each option for my situation?
• What does the initiation process look like?
• How will this medication interact with my other health conditions or medications?
• What happens if this medication does not work for me?

---

This glossary entry is part of our Addiction Treatment Glossary. For more on Vivitrol specifically, see What Is Vivitrol? and The Vivitrol Program: Cost and Practical Details. To understand Suboxone’s role in opioid treatment, visit our guide on Suboxone treatment. For a broader overview of medication-assisted treatment, see MAT for opioid addiction.